Real World Evidence

Webinar Date/Time: Mon, Dec 2, 2024 11:00 AM EST

Webinar Date/Time: Tuesday, December 10th, 2024 at 11am EST | 8am PST | 4pm GMT | 5pm CET

Webinar Date/Time: Wednesday, November 13th, 2024 at 11am EST | 8am PST | 4pm GMT | 5pm CET

Webinar Date/Time: Thursday, September 12th, 2024 at 11am EDT|8am PDT|4pm BST|5pm CEST

Webinar Date/Time: Thursday, May 9th, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

Webinar Date/Time: Tue, Mar 26, 2024 11:00 AM EDT

Webinar Date/Time: Wed, Mar 27, 2024 11:00 AM EDT

Webinar Date/Time: Tue, Oct 17, 2023 11:00 AM EDT

Webinar Date/Time: Thursday, May 25th, 2023 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

Webinar Date/Time: Thu, May 4, 2023 10:00 AM EDT

Webinar Date/Time: Wednesday, March 29th, 2023 at 11am | 8am PDT | 4pm BST | 5pm CEST

Webinar Date/Time: Tue, Mar 28, 2023 11:00 AM EDT

Webinar Date/Time: Thu, Mar 16, 2023 11:00 AM EDT

Webinar Date/Time: Mon, Feb 13, 2023 10:00 AM EST

Webinar Date/Time: Tuesday, December 13, 2022 at 10am ET | 3pm GMT | 4pm CET

Survey among readers evaluates the trajectory of RWD and how it can be more widely adopted.

Addressing sources of tension on differentiating types of data.

By integrating real-world data more deeply into the process of clinical research, life sciences stakeholders can open up new possibilities for therapeutic development and the evidence-based treatment of hematologic cancers.

RWE can augment, extend, or enrich the findings from clinical trials to provide valuable evidence to support the development programs for product approvals.

C.K. Wang, MD, senior medical director at COTA Inc., discusses the impact of RWD and RWE in clinical oncology.

A look at the scope of the agency’s draft framework for evaluating the use of RWE to support new drug approvals and the implications for sponsors.

With outcomes from “real life” a critical compliment to clinical trial data, the importance of involving an epidemiologist at study inception is explored.

Karen Hill and Heather Fitzpatrick Medlin discuss the recent advancements and challenges in cardiovascular and metabolic studies, as well as strategies to address current obstacles and advance the industry further.

Study examines the growing integration of real-world data and evidence and the remaining roadblocks to adoption.    

In this three-part blog series, we look at how electronic platforms can support and enhance data capture in several types of RWD programs: observational studies, pragmatic trials, and commercial programs.

In this three-part blog series, we look at how electronic platforms can support and enhance data capture in several types of RWD programs: observational studies, pragmatic trials, and commercial programs.

In this three-part blog series, we look at how electronic platforms can support and enhance data capture in several types of RWD programs: observational studies, pragmatic trials, and commercial programs.

How pragmatic clinical trials increase the robustness of real world studies at a fraction of the cost of classical randomized controlled clinical trials.

The early implementation of post authorization safety studies (PASS) will translate to efficiencies in pre-appoval research. These benefits allow for faster approval and wider patient access to potentially life saving therapies.

Forging new partnerships focused on the safety of long-acting opiates is important, as public health questions surrounding drug abuse and addiction have increased, along with regulations governing these products once they reach the market.